Dr. Constance T. Albarracin, MD, PhD

Dr. Albarracin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Albarracin's NPI, 1255424073, was assigned on October 2, 2006. Dr. Albarracin graduated from University of Santo Tomas in 1984. Dr. Albarracin holds Texas license L5646.

Dr. Albarracin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Albarracin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albarracin practices. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Albarracin's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Albarracin is board certified in anatomic pathology & clinical pathology by the American Board of Pathology. Dmand AI has Dr. Albarracin's licenses on file in 2 states: Texas and Illinois.

CMS data shows 1,166 Medicare services from Dr. Albarracin across 9 procedure codes in 2024, for 285 Medicare patients. Medicare paid $41,771 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 285 Medicare patients who saw Dr. Albarracin in 2024. The largest group is 65 to 74, with 176 patients. 75% of them have cancer, and 74% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Albarracin's median patient age at 57, with 97% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Albarracin for performance year 2024, reported as part of a group. Dr. Albarracin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 72 papers to Dr. Albarracin, published from 2007 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Immunohistochemistry and Receptor, ErbB-2. Dr. Albarracin has published most often in Breast Cancer Res Treat. Dr. Albarracin's most frequent co-authors are Yun Wu, MD, PhD, Lei Huo, MD and Hui Chen, MD, PhD.

CMS Open Payments shows 1 general payment to Dr. Albarracin from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $100.

Dr. Albarracin graduated from University of Santo Tomas in 1984.

Dr. Albarracin is in network with 8 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.